About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Pulsenmore ES Device, Efficacy and Safety Assessment

NCT05329077·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

PulseNmore

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Singleton gestation.
Gestational age \>14 weeks with a prior scan demonstrating fetal viability and confirming dates.
English or Spanish speaking.
Ability to understand and sign the informed consent (available in English and Spanish).
Ability to read and understand instructions that are required for equipment use (instructions available in both languages).

You may not be if

Multiple gestations.
BMI \>40.
Known fetal and genetic anomalies.
Subjects with skin problems in the abdominal area (such as wounds, cuts in the skin, and skin rash).
Subjects allergic to the ultrasound probe materials.
Non-English/ non-Spanish speaking.
Unable to provide consent.

The record

StatusCompleted

PhaseNo phase

Taking part188

StartedApr 2022

UpdatedNov 30, 2023

Conditions

Where4

Center for Fetal Medicine and Women's Ultrasound
Los Angeles, California, United States
University of Florida College of Medicine
Gainesville, Florida, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States

Clareo Health | Pulsenmore ES Device, Efficacy and Safety Assessment